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Abstract: Human and canine mammary tumours show partial claudin expression deregulations.
Further, claudins have been used for directed therapeutic approaches. However, the development
of claudin targeting approaches requires stable claudin expressing cell lines. This study reports the
establishment and characterisation of canine mammary tissue derived cell lines, analysing longitudinally
the claudin-1, -3, -4 and -7 expressions in original tissue samples, primary cultures and developed cell
lines. Primary cultures were derived from 17 canine mammary tissues: healthy, lobular hyperplasia,
simple adenoma, complex adenoma, simple tubular carcinoma, complex carcinoma, carcinoma
arising in a benign mixed tumour and benign mixed tissue. Cultivation was performed, if possible,
until passage 30. Claudin mRNA and protein expressions were analysed by PCR, QuantiGene
Plex Assay, immunocytochemistry and immunofluorescence. Further, cytokeratin expression was
analysed immunocytochemically. Cultivation resulted in 11 established cell lines, eight showing
epithelial character. In five of the early passages the claudin expressions decreased compared to the
original tissues. In general, claudin expressions were diminished during cultivation. Three cell lines
kept longitudinally claudin, as well as epithelial marker expressions, representing valuable tools for
the development of claudin targeted anti-tumour therapies.
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1. Introduction
The claudin (CLDN) protein family is a major structural and functional component of the tight
junction complex in epithelial and endothelial cells [1–3]. Changes in the CLDN expressions were
found in human and canine epithelial neoplasms of the mammary gland [4–6], human prostate [7,8],
canine pancreas [9,10], colorectum of both species [11–15] and evaluated regarding the diagnostic
potential of those proteins. Furthermore, CLDN proteins act as a receptor for the enterotoxin of
Clostridium perfringens (Clostridium perfringens enterotoxin, CPE), a feature that enables a directed CLDN
targeting for therapeutic approaches [16,17]. This feature was already used to successfully kill human
CLDN-3 and -4 expressing cells in vivo and in vitro [7,16–19]. Directed recombinant mutation of the
CPE sparing the cytotoxic domain leads to a protein that allows a directed reversible binding of CLDN
proteins without killing the targeted cell [19–21]. This enables drug delivery to CLDN expressing
cells [22]. Thus, CLDN targeting has been discussed to represent a new therapeutic option for CLDN
expressing tumours, although side effects appearing in CLDN expressing non-neoplastic cells have to
be considered. Consequently, a potential application should be carefully chosen, e.g., intratumoural
injections for local application [5,7,18,19,23–25]. Tumour derived cell lines are a key tool for in vitro
evaluation of CLDN targeting as a therapeutic option. Furthermore, understanding the regulation of
CLDN expressions in tumour cells increases general insights in tumour biology. In general, cell lines
can also serve in comparative cancer genetics and translational medicine, as reported for canine lung
tumour derived cell lines, showing genetic and biochemical similarities to human lung tumours and
promising effects of a drug effective in human tumours on these cell lines [26].
Several studies indicated that cells derived from human and canine tumours reduce their CLDN
expressions during cultivation [4,7,18,27]. Consequently, the CLDN expression profiles of cell lines
do not always reflect the expression profiles of the original tissues. Thus CLDN-expressing tumour
derived cell lines, keeping the CLDN expressions, are of major value for tumour research.
This study reports comparative CLDN-1, -3, -4 and -7 expression analyses of non-neoplastic and
neoplastic canine mammary gland tissue samples and thereof derived primary cultures and cell lines.
The aim of the study was to identify stable CLDN expressing canine mammary gland derived cell
lines, keeping the initial epithelial character.
2. Results
2.1. Cell Cultivation and Analyses of the Epithelial Character
2.1.1. Primary Cultures
Six of the 17 primary cultures discontinued growth before reaching p.19: three of the
five healthy tissues derived primary cultures (DT14/04R, DT14/05S2, DT14/07R), one of two lobular
hyperplasia derived primary cultures (DT14/08R) and both simple carcinoma derived primary cultures
(DT14/07T, DT14/09T). For details see Table 1.
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Table 1. This table shows the cell lines and primaray cultures and the corresponding histological classification (“Histological classif.”) of the original tissue samples.
An “X” marks the tissues and cell pellets (“p.n”) that were available for gene expression analyses using QuantiGene Plex Assay.
Cell Line Histological Classif. Tissue p.00 p.01 p.02 p.03 p.05 * p.07 * p.08 * p.10 p.16 p.20 p.30 p.40
DT14/05R non-neoplastic mammary gland tissue X X X X
DT14/06R X X X X X X
T124 lobular hyperplasia X X X X
DT14/04T simple adenoma X X X X X
T121 complex adenoma X X X
T120A
carcinoma, complex type
X X X
DT14/06T X X X X X X
DT14/06Ts X X X X X
T126 carcinoma arising in a benign mixed tumour X X X X
DT14/10 benign mixed mammary tumour X X X X
DT15/02T X X X X
Primary Culture Histological Classif. Tissue p.00 p.01 p.02 p.03 * p.05 p.07 p.08 p.10 p.16 p.20 p.30 p.40
DT14/04R
non-neoplastic mammary gland tissue
X X ** ** **
DT14/05S2 X X X ** ** **
DT14/07R X X X ** ** **
DT14/08R lobular hyperplasia X X X X ** ** **
DT14/07T simple tubular carcinoma X X X X ** ** **
DT14/09T X X X X ** ** **
“*” p.05, 07 and 08 of cell lines had not been analysed, p.03 of primary cultures had not been analysed; “**” p. > 19 of primary cultures do not exist, as primary cultures were designated
as cell lines in case they reached p.19 and above.
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For the evaluation of the epithelial character, early and late passages were immunocytochemically
analysed for cytokeratin distribution. DT14/04R and DT14/05S2 did not exhibit any cytokeratins.
DT14/07T partially kept the distribution of cytokeratins. DT14/08R and DT14/09T lost the
cytokeratins. DT14/07R added on cytokeratins. For details see Table 2.
Table 2. This table shows the cytokeratin (CK) distribution of the primary cultures. “Histological
Classif.” refers to the histological classification of the original tissue samples from which the primary
cultures were derived, “p.n” refers to a certain passage, “AE1/AE3” refers to Pan-CK (CK1-8, CK10,
CK13-16, CK19), “MNF116” refers to Pan-CK (CK5, CK6, CK8, CK17, CK19), “HMW” refers to Pan-CK
(CK1, CK5, CK10, CK14). “+” refers to positivity, “(+)” to a weak positivity and “−” refers to negativity
for protein distribution. “NA” refers to not available.
Primary
Culture
Histological
Classif. p.n AE1/AE3 MNF116 HMW CD5/6 CK7 CK10 CK14 CK20
DT14/04R
healthy
mammary
gland tissue
p.08 −
p.13 −
DT14/05S2
p.04 −
later NA
DT14/07R
p.03 − (+) − (+) −
p.07 + + − + + − + −
DT14/08R
lobular
hyperplasia
p.02 (+) −
p.05 −
DT14/07T simple
tubular
carcinoma
p.03 + + + + (+) − + −
p.17 + + + (+) − + −
DT14/09T
p.03 + (+) (+) − (+) −
p.08 −
2.1.2. Cell Lines
Eleven of the 17 primary cultures proliferated until p.19 and beyond and therefore resulted in
cell lines: two of the five healthy tissue derived primary cultures (DT14/05R, DT14/06R), one of the
two lobular hyperplasia derived primary cultures (T124), eight of the twelve neoplastic tissue derived
primary cultures (simple adenoma derived (DT14/04T), complex adenoma derived primary cultures
(T121), complex carcinoma derived primary cultures (T120A, DT14/06T, DT14/06TS), carcinoma
arising in a benign mixed tumour derived primary culture (T126), benign mixed mammary tumours
derived primary cultures (DT14/10, DT15/02T). For details see Table 1.
Seven cell lines partially kept the distribution of cytokeratins (T124, T121, T120A, DT14/06T,
DT14/06TS, DT14/10, DT15/02T). Three cell lines lost the cytokeratins (DT14/05R, DT14/06R, T126).
One cell line added on cytokeratins (DT14/04T). For details see Table 3.
2.2. CLDN Gene Expression Analyses
2.2.1. Gene Expression Analyses: QuantiGene Plex Assay
The QuantiGene Plex Assay allowed the simultaneous multiplexing of all genes of interest
(CLDN-1, -3, -4, -7, β-Actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)) in RNAs
of all examined passages of the primary cultures, cell lines and available original tissue samples via
amplified fluorescence detection. Furthermore, all passages of the primary cultures, cell lines and the
original tissue samples were analysed in one run. CLDN expressions were normalized to the reference
genes ACTB and GAPDH revealing similar results. ACTB and GAPDH were chosen as they were
already used for CLDN gene expression analyses in canine prostate tumour and mammary tissue and
tumour derived cell lines [27]. Furthermore, they were used for CLDN gene expression analyses of
human tissues and intestinal carcinomas [13,14,28,29]. If a CLDN expression was normalized only to
ACTB or GAPDH it is clearly stated within the text.
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Table 3. This table shows the cytokeratin (CK) distribution of the cell lines. “Histological Classif.”
refers to the histological classification of the original tissue samples from which the cell lines were
derived, “p.n” refers to a certain passage, “AE1/AE3” refers to Pan-CK (CK1-8, CK10, CK13-16, CK19),
“MNF116” refers to Pan-CK (CK5, CK6, CK8, CK17, CK19), “HMW” refers to Pan-CK (CK1, CK5, CK10,
CK14). “+” refers to positivity, “(+)” to a weak positivity and “−” to negativity for protein distribution.
“NA” refers to “not available”.
Cell Line Histological Classif. p.n AE1/AE3 MNF116 HMW CK5/6 CK7 CK10 CK14 CK20
DT14/05R
healthy mammary
gland tissue
p.04 (+) − (+) −
p.21 −
DT14/06R
p.04 (+) (+) − (+) −
p.41 − NA NA NA NA NA NA NA
T124 lobular hyperplasia
p.03 + + + + (+) (+) + −
p.36 + + + + + − + −
DT14/04T simple adenoma
p.05 + + (+) (+) − − −
p.27 + + − + + − + −
T121 complex adenoma
p.06 (+) (+) (+) (+) − + −
p.28 (+) − (+) − + −
T120A
carcinoma complex
type
p.07 (+) (+) (+) (+) (+) − + −
p.44 + + + − + −
DT14/06T
p.04 (+) − (+) −
p.43 (+) −
DT14/06Ts
p.04 (+) (+) (+) − (+) −
p.33 (+) −
T126
carcinoma arising in
a benign mixed tumour
p.03 − (+) −
p.24 −
DT14/10
benign mixed
mammary tumour
p.02 + + NA − (+) − + −
p.31 + + NA − + −
DT15/02T
p.04 + (+) + − + −
p.45 (+) − (+) − (+) −
CLDN Gene Expression Alterations from Tissue Samples to Passage 00
Alterations of the CLDN expressions presumably result from dissociating cells from the tissue
matrix in the process of exposing them to cultivation. These alterations were analysed in three primary
cultures and three cell lines by comparing the gene expressions of the original tissue samples and the
corresponding first passage (p.00).
In all three analysed primary cultures and all three analysed cell lines, the CLDN-1, -3,
-4 and -7 gene expressions decreased in relation to GAPDH, comparing the original tissue samples and
the corresponding first passage. In five of six cell cultures the CLDN-1, -3, -4 and -7 gene expressions
decreased in relation to ACTB. In one cell culture the CLDN-1, -4 and -7 gene expressions increased
in relation to ACTB. However, in that cell culture CLDN-3 expression decreased in relation to ACTB.
For details see Figure 1.
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expression of the reference genes ACTB and GAPDH) in the latest analysed passage were displayed 
for CLDN-1 by four cell lines (T124, DT14/04T, T120A and DT14/10), for CLDN-3 by two cell lines 
(T124 and T120A) and for the CLDNs-4 and -7 by three cell lines (T124, DT14/04T and T120A). For 
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CLDN Gene Expressions in the Latest Analysed Passage
High DN gene expression levels (cut off was set at level 0.1, referring to level 1 as gene
expression of the reference genes ACTB and GAPDH) in the latest analysed passage were displayed
for CLDN-1 by four cell lines (T124, DT14/04T, T120A and DT14/10), for CLDN-3 by two cell lines
(T124 and T120A) and for the CLDNs-4 and -7 by three cell lines (T124, DT14/04T and T120A).
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Figure 2. CLDN gene expression profiles of canine mammary non-neoplastic and neoplastic tissue
derived cell cultures during cultivation until passage 30: Cell lines T120A, T124, DT14/04T and
DT14/10 exhibited high CLDN-1 (a,b) gene expressions; in the other cell cultures the expression was
below 0.1 (CLDN-1 relative to ACTB and GAPDH respectively: T120A: 0.58, 0.56; T124: 0.61, 0.56;
DT14/04T: 0.59, 0.51; DT14/10: 0.12, 0.11); Cell lines T120A and T124 exhibited high CLDN-3 (c,d)
gene expressions; in the other cell cultures the expression was below 0.1 (CLDN-3 relative to ACTB
and GAPDH respectively: T124: 0.47, 0.43; T120A: 0.30, 0.29); Cell lines T124, DT14/04T and T120A
exhibited high CLDN-4 (e,f) and -7 (g,h) gene expressions; in the other cell cultures the expression was
below 0.1 (CLDN-4 relative to ACTB and GAPDH respectively: T124: 0.66, 0.60; DT14/04T: 0.35, 0.30;
T120A: . 9, 0.38; CLDN-7 relative to ACTB and GAPDH respectively: T124: 0.74, 0.68; DT14/04T: 0.34,
0.30; T120A: 0.14, 0.14).
CLDN Gene Expression Profiles during Cultivation (Passages 00 until Passage 30)
The CLDN-1, -3, -4 and -7 gene expression levels decreased in the majority of the analysed
primary cultures and cell lines in the beginning of the cultivation and remained low (lower than 0.1)
during cultivation.
Cell lines T120A and T124 showed high CLDN expression levels for the CLDN-1, -3, -4 and -7 genes.
Cell line DT14/04T exhibited high CLDN expression levels for the CLDN-1, -4 and -7 genes. Therefore,
the CLDN gene expression profiles were described for cell lines T120A, T124 and DT14/04T.
T120A: Cell line T120A was analysed in p.10, p.20 and p.30. Generally, the CLDN-1, -3 and
-4 expressions were higher than the CLDN-7 expression. Regarding the expression profiles from p.10 to
the latest analysed p.30, the CLDN-1, -3 and -7 gene expressions increased. The CLDN-4 expression
increased from p.10 to p.20 but decreased slightly from p.20 to p.30.
T124: Cell line T124 was analysed in p.02, p.10, p.20 and p.30. Passage 30 displayed comparable
expression levels for the CLDN-1, -3, -4 and -7 genes. Regarding the expression profiles from p.02 to p.30,
the CLDN gene expressions i cre se . Regarding the expression profiles from p.20 to p.30 the CLDN-4
gene expression increased, whereas the CLDN-1, -3 and -7 gene expressions decreased moderately.
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DT14/04T: Cell line DT14/04T was analysed in p.03, p.10, p.20 and p.30. CLDN-1, -3, -4 and
-7 expression levels of the latest analysed p.30 were at high levels. However, a decrease of expression
was observed from p.10 for CLDN-3 and -7 and from p.20 for CLDN-1 and -4.
Linear Correlation of CLDN Expression during Cultivation
Analyses of the correlation of CLDN gene expressions during cultivation revealed highly
correlating CLDN gene expression profiles in cell line T120A for the CLDN-1/-3, -1/-4 and -3/-4 genes,
in cell line T124 for the CLDN-1/-3 and -4/-7 genes and in cell line DT14/04T for the CLDN-1/-4 and
-3/-7 genes. For details see Figure 3.
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Figure 3. The temporal CLDN gene expression profiles during cultivation showed highly correlating
CLDNs within cell line T120A for the CLDN-1/-3, -1/-4 and -3/-4 genes (in relation to ACTB (a)
respectively 0.99; 0.91; 0.96, and in relation to GAPDH (b) respectively 0.98; 0.90; 0.97), within cell line
T124 for the CLDN-1/-3 and -4/-7 genes (in relation to ACTB (c) respectively 0.94; 0.95, and in relation
to GAPDH (d) 0.97; 0.93) and within cell line DT14/04T for the CLDN-1/-4 and -3/-7 genes (in relation
to ACTB (e) respectively 0.90; 0.98, and in relation to GAPDH (f) 0.90; 0.97).
2.2.2. Gene Expression Analyses: Conventional PCR
CLDN-1, -3, -4 and -7 gene expressions were analysed using conventional PCR in cDNA of early
and late passages of cell cultures T120A, T121, T124, DT14/04R, DT14/04T, DT14/06T and DT14/10
allowing a qualitative statement. Previous to the conventional PCR, contamination with genomic DNA
were excluded for all cDNAs using a primer assay for an intro sequence of C-X-C chemokine receptor
type 4 gene.
CLDN-1 gen xpressi n was equal in four cell lines (T120A, T124, DT14/04T; DT14/10) and
one primary culture (DT14/04R). In two cell lines (DT14/06T, T121), CLDN-1 expression differed
from negative in the early to positive in the late passage. CLDN-3 gene expression was equal in
three cell lines (T120A, T124, DT14/04T) and lost in another cell line (DT14/06T). In one primary
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culture (DT14/04R) CLDN-3 expression differed from negative in the early to positive in the late
passage and in two cell lines (T121, DT14/10) the other way round. CLDN-4 gene expression was equal
in three cell lines (T120A, T124, DT14/04T) and lost in three cell lines (T121, DT14/06T, DT14/10).
In one primary culture (DT14/04R) CLDN-4 expression differed from negative in the early to positive
in the late passage. CLDN-7 gene expression was equal in three cell lines (T120A, T124, DT14/04T) and
lost in two cell lines (DT14/10, DT14/06T). In one primary culture CLDN-7 gene expression differed
from negative in the early to positive in the late passage (DT14/04R) and the other way round in
one cell line (T121). For details see Table 4.
Table 4. This table shows the respective CLDN-1, -3, -4 and -7 gene expressions for cell lines T120A,
T124, DT14/04T, DT14/04R, DT14/10, DT14/06T and T121 in early (“e.p.”) and late (“l.p.”) passages
obtained by conventional PCR. “+” refers to positive expression, “−” refers to no expression.
Gene CLDN-1 CLDN-3 CLDN-4 CLDN-7
passage e.p. l.p. e.p. l.p. e.p. l.p. e.p. l.p.
T120A + + + + + + + +
T124 + + + + + + + +
DT14/04T + + + + + + + +
DT14/04R + + − + − + − +
DT14/10 + + + − − − − −
DT14/06T − + − − − − − −
T121 − + + − − − + −
2.3. Immunocytochemistry
Immunocytochemistry detected CLDN-1, -3, -4 and -7 proteins in cell cultures T120A, T124,
DT14/04T, DT14/04R, DT14/10, DT14/06T and T121. The late passages of cell cultures DT14/04T and
DT14/10 lacked CLDN-4 protein.
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Figure 4. CLDN protein distribution and localization in cell lines T120A (p.37–42), T124 (p.12),
DT14/04T (CLDN-1, -3 and -7: p.16-19; CLDN-4: p.5) and DT14/06T (p.44–49) as detected by IF.
Cells were fixed and stained f r CLDN-1, -3, -4 and -7 usi g fluorescein or FITC (fluorescein
isothiocyanate) conjugated secondary antibodies, which are visible in green, and for nuclei using
DAPI (4′,6-diamidino-2-phenylindol), which is visible in blue. Arrows indicate CLDN localization at
cell–cell contacts. Scale bar: 20 µm.
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2.4. Immunofluorescence
Immunofluorescence revealed a cell specific expression of the CLDN-1, -3, -4, and -7 proteins.
While cell line DT14/06T p.44–49 did not show an expression of the CLDNs, cell lines T120A, T124 and
DT14/04T did. The expression of CLDN-1, -3 and -4 proteins was found in cell line T120A p.37–42
at the cell membrane, but there was no signal for CLDN-7. All four analysed CLDN-1, -3, -4 and
-7 proteins were found in cell line T124. In cell line T124 p.15 the CLDN-3 and -7 proteins were
localized at the cell membranes, CLDN-1 and -4 were punctually localized in the cytoplasm. In cell
line DT14/04T p.16–19 CLDN-1 and -7 proteins were strongly distributed in the cell-to cell contact
regions, CLDN-4 was weakly expressed in p.5 and CLDN-3 was not detected in p.16–19. For details
see Figure 4.
3. Discussion
Mammary tumours commonly occur in female dogs [30]. Treatment options are restricted to
invasive options such as surgery and, additionally, chemotherapy in the case of metastasis [31].
Retrospective studies exploring cytotoxic agents are mostly restricted to a limited number of dogs,
included in the respective studies. Complex prospectivly conducted studies evaluating experimental
therapeutic protocols are practically missing [32]. However, the establishment of non-invasive
therapeutic approaches for mammary carcinomas is currently addressed in various ways. A recent
study reported a non-invasive treatment option for mammary tumours in dogs and cats using
plasmonic photothermal therapy [33]. Due to disease similarities between humans and dogs,
similar environmental conditions, but easier performable trials (guidelines are less strict than for
humans), dogs are considered to represent an excellent model for human diseases [34]. Accordingly,
data obtained by canine tumour research may also lead to progress in human tumor research.
Further experimental therapeutic approaches targeting human cancer cells include the use of the
enterotoxin of Clostridium perfringens (CPE) in order to kill cancer cells by directed CLDN binding.
In a xenografical mouse model, the intratumourally injected CPE reduced the size of CLDN expressing
tumours initiated by a human breast cancer cell line [5]. A recombinant CPE-tumour necrosis factor
fusion protein inhibited growth of CLDN expressing human ovarian tumour cells [22]. Human ovarian
tumour cells overexpressing CLDNs-3 and -4, injected into mice, were selectively killed by the
administration of CPE [18]. Further, CLDN-3 and -4 expressing cells from a human prostate carcinoma
bone marrow metastase were killed in vitro by adding the CPE to the culture medium [7]. Additionally,
mutated recombinant CPE fragments are in experimental evaluation as for example the non-toxic but
CLDN binding C-terminal fragment (C-CPE), which is able to inhibit the growth of CLDN expressing
tumour cells [5,16,22,24]. A combination of the C-CPE and taxol enhanced chemosensitivity of human
ovarian cancer cells and inhibited tumour growth of such cells in a xenografic mouse model [24].
In order to develop specific CLDN targeting therapeutic approaches for canine mammary gland
tumours, the availability of CLDN expressing cell lines is a precondition. In the present study,
comparative CLDN gene and protein expression analyses on eleven cell lines and six primary cultures
derived from canine mammary gland non-neoplastic and neoplastic tissues were performed. In the
majority of the herein analysed cell lines and primary cultures (fourteen of seventeen) the CLDN-1, -3,
-4 and -7 gene expressions decreased after transfer to culture conditions when compared to the original
tissue samples. Furthermore, CLDN expressions remained low during longitudinal cultivation over
30 passages. These results match our previously published study, showing low to missing CLDN
expression in long term established canine mammary non-neoplastic and neoplastic tissue derived cell
lines ZMTH3, MTH53A and MTH52C [27]. Further studies evaluating CLDN expression in different
tumour types reported a decrease or lack of CLDN-3, -4 and -7 expressions of in vitro cultured cells
compared to uncultured cells [4,7,18]. Human prostate carcinoma metastases derived cell lines PC3 and
LNCaP lack CLDN-3 and -4 expressions, whereas human non-neoplastic prostate epithelium expresses
the CLDNs-3 and -4 [7]. A 1000-fold lower CLDN-7 expression was found in cultivated human
mammary endothelial cells (HMECs) compared to uncultured HMECs [4]. A comparable decrease
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regarding CLDN-3 and -4 gene expression patterns was reported for cultured human ovarian cancer cell
lines that show a lower CLDN expression than primary ovarian tumours [18]. The reason for CLDN
expression or repression for the tumour cells is not fully understood. It has been proposed that the
loss of CLDNs allows the loss of cell polarity, thereby promoting the tumorigenesis [35]. Metastasis is
a process linked to advanced tumour stage, in which cells dissociate from a tumour, enter blood or
lymphatic vessels, attach in distant sites and form new tumours [36]. Epithelial-to-mesenchymal
transition (EMT) is linked to metastasis [37] and it is suggestive that loss of CLDNs contributes to
this process [12,29]. However, the role of CLDNs in EMT is not yet elucidated. As in cultured cells,
the complex three dimensional structure of tissues is non-existent, the observed down regulation can
be caused by the loss of required CLDN functions.
However, in three of the herein evaluated new established canine mammary cell lines (originating
from respectively a lobular hyperplasia, a carcinoma and an adenoma) expression of the CLDN genes
increased comparing an early passage and p.30, but did not reach constant expression levels before p.30.
Further, these cell lines kept the epithelial character throughout the observed cultivation period. To the
best of our knowledge, this is the first study to longitudinally analyse the CLDN expressions up to
passage 30. Comparisons to other studies are difficult as information about the analysed passages
are missing.
Correlation coefficient analyses of the three CLDN expressing cell lines identified in the present
study indicated that culturing conditions do not affect all CLDNs in the same manner. These findings
might be associated to the functional ability of different CLDNs to specifically heterophilically interact
with each other. CLDN-3 is able to interact heterophilically with CLDN-1 or CLDN-2, whereas the
latter are not able to interact with each other [38]. Immunofluorescence revealed that CLDN-1 and
-4 proteins in cell line T124 were located in the cytoplasm, whereas the CLDN-3 and -7 proteins were
located at the cell membranes, where the CLDN proteins are supposed to be located [39]. Such apparent
mislocalizations were also described for the CLDN-3 protein in human breast cancer derived cell
lines and may be related to local invasiveness [40]. These findings should receive attention in studies
evaluating the CLDNs as a target for anti-tumour therapies.
In summary, the data reported here show that cultivation of canine mammary cells has negative
effects on the expression of different CLDNs. However, three epithelial canine mammary lobular
hyperplasia, adenoma and carcinoma derived cell lines kept the expression of the analysed CLDN
genes and proteins during cultivation until p.30. These three canine mammary gland tissue derived
CLDN expressing epithelial cell lines represent valuable tools for further studies regarding CLDN
targeted tumour therapeutic approaches.
4. Materials and Methods
4.1. Material, Cell Cultivation and Sample Processing
4.1.1. Canine Mammary Gland Tissue Samples
Five normal canine mammary gland tissue samples, two lobular hyperplasias, one simple
adenoma, one complex adenoma, two simple carcinomas, three complex carcinomas, one carcinoma
arising in a benign mixed tumour and two benign mixed mammary tumours were provided by
the Small Animal Clinic, University of Veterinary Medicine Hannover, Germany, the Institute of
Veterinary Medicine, Georg-August-University Göttingen, Germany, and the veterinary practice of
Dr. M. Schilling, Bielefeld, Germany; in total 17 canine mammary gland tissue samples.
Samples for diagnostic procedures were stored in formalin. Histological classification was
performed in the Department of Pathology of the University of Veterinary Medicine Hannover,
Germany, according to the proposed classification of canine mammary tumours [41]. Depending on the
size of the tissue samples, portions for gene expression analyses were shock frozen in liquid nitrogen
and stored at −80 ◦C until RNA was isolated using the RNeasy® Mini Kit (Qiagen, Hilden, Germany).
For details see Table 1.
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4.1.2. Establishment of Primary Cultures
Non-neoplastic and neoplastic tissue samples were stored in Hanks Medium (Hank’s salts
L201-00, Biochrom GmbH, Berlin, Germany), 2% penicillin and streptomycin (Biochrom GmbH, Berlin,
Germany) until being processed. A small portion of the initial tissue sample was chopped into small
pieces followed by collagenase treatment (0.35% Collagenase NB 8 Broad Range, SERVA Electrophoresis
GmbH, Heidelberg, Germany) at 37 ◦C until cell connections dissolved, for a maximum of 4 h.
The dissociated cells were washed with medium 199 (Gibco by Life technologiesTM, Darmstadt,
Germany) containing 20% fetal calf serum (FBS Superior, Biochrom GmbH, Berlin, Germany) and
200 IU/mL penicillin and 200 mg/mL streptomycin (Biochrom GmbH, Berlin, Germany). Afterwards,
cells were transferred into sterile 25 cm2 flasks containing 5 mL medium 199 (20%). The cultures were
incubated in 5% CO2/air at 37 ◦C. During the first days, the cells were monitored on a daily basis
observing cell growth, depending on respective characteristics. The culture medium was changed at
least twice per week. Reaching confluency, the cells were passaged by adding 1 mL TrypLETM Express
([-] Phenol Red, Gibco by Life technologiesTM, Darmstadt, Germany) and then the cell suspension was
split and transferred to sterile cell culture flasks, containing 5 mL medium 199 (20%) per flask.
The cells dissolved from the initial tissue sample were herein indicated as passage (p.) 00 (p.00).
After first splitting, the cells were termed p.01, higher numbers indicate the number of the certain
passage. The term “primary culture” referred to cell cultures between p.00 and p.19. Reaching p.20
and above, the certain “primary culture” was furthermore designated as “cell line”.
Primary cultures were analysed in p.00 and additionally in another early passage (p.01, p.02).
In case cell growth discontinued before the tenth passage, the latest viable passage was analysed.
In case cells grew beyond p.10 but discontinued growth before p.19, then p.10, and additionally the
latest viable passage, were analysed.
Cell lines were analysed in p.00, in an early passage (p.01–p.03) and then in p.10, p.20 and p.30.
Depending on the cell number of a passage, pellets were generated according to Table 1 and
stored adequately.
4.1.3. Generation of Cell Pellets
The cells were detached by adding 1 mL TrypLETM Express ([-] Phenol Red, Gibco by Life
technologiesTM, Darmstadt, Germany) to the flasks. The cells were counted using Cellometer SD100
cell counting chambers (Nexcelom Bioscience, Lawrence, MA, USA) and CellometerTM Auto T4
(Nexcelom Bioscience), pelleted at 1000 g for 10 min and stored adequately until further usage.
For histological analyses, pellets were stored in 4% paraformaldehyde. For gene expression
analyses, using either QuantiGene Plex Assay (Affymetrix, Santa Clara, CA, USA) or conventional
PCR, cell pellets were stored at −80 ◦C.
4.1.4. Cell Lysis for Gene Expression Analysis Using QuantiGene Plex Assay (Affymetrix)
Cells were lysed at a final concentration of 400 cells/µL Lysis Mixture using the QuantiGene
Sample Processing Kit (Affymetrix), according to the manufacturer’s instructions. Lysates were stored
at −80 ◦C until usage.
4.1.5. RNA-Isolation from Tissue Samples for Gene Expression Analyses Using QuantiGene Plex
Assay (Affymetrix)
5–30 mg of frozen tissue samples were homogenized using the Tissue Lyser II (Qiagen, Hilden,
Germany) and 5 mm Stainless Steel Beads (Qiagen) according to the manufacturer’s instructions
(Qiagen). RNA was isolated using the RNeasy® Mini Kit (Qiagen) including a digestion step for
genomic DNA using the RNase-Free DNase Set (Qiagen) according to the manufacturer´s instructions.
An additional step for digestion of genomic DNA was performed using RQ1-DNAse (Promega,
Mannheim, Germany) according to the manufacturer’s instructions. The total amount of RNA was
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quantified using Synergy 2 (Biotek, Bad Friedrichshall, Germany) controlled by Gen5™ Reader Control
and Data Analysis Software. RNAs were stored at −80 ◦C until usage.
4.1.6. RNA-Isolation from Cultured Cells for Gene Expression Analyses Using Conventional PCR
Cells were homogenised using QIAshredderTM columns (Qiagen). RNA was isolated using the
RNeasy® Mini Kit (Qiagen), RNase-Free DNase Set (Qiagen) and RQ1-DNAse (Promega) as described
in Section 4.1.5. Measurement of the amount of RNA and storage was performed as described in
Section 4.1.5.
4.2. Gene Expression Analyses
4.2.1. CLDN Gene Expression Analyses Using QuantiGene Plex Assay (Affymetrix)
CLDN-1, -3, -4, -7, β-actin (ACTB) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene
expressions were simultaneously analysed in isolated RNA (12.5 ng/µL) of canine mammary
non-neoplastic and neoplastic tissue samples and cell lysates (400 cells/µL) of different passages
of thereof derived primary cultures and cell lines using QuantiGene Plex Assay (Affymetrix)
according to the manufacturer’s instructions, Vortemp 56 (Labnet International, Inc., Edison, NJ, USA)
and Luminex 100/200 Systems (Luminex Corporation, Austin, TX, USA). Luminex 100/200 Systems
detected the amplified fluorescence signals generated by the QuantiGene Plex Assay (Affymetrix).
For each run, background controls and process controls were performed as duplicates. As process
controls, samples that were to be analysed were chosen. Samples were run as unicates. Normalization was
performed towards two reference genes, ACTB [13] and GAPDH [42]. Available tissue samples and
passages of the corresponding cell cultures were analysed according to Table 1.
Probes for the QuantiGene Plex Assay (Affymetrix) were ordered based on the mRNA sequences
provided by the National Center for Biotechnology Information (NCBI) and custom designed by
Affymetrix (Santa Clara, CA, USA). The accession numbers for the mRNA sequences were as follows:
CLDN-1: XM_845155; CLDN-3: NM_001003088; CLDN-4: XM_005620962; CLDN-7: XM_546584;
ACTB: XM_536888; GAPDH: NM_001003142.
CLDN Gene Expression in the Original Tissue Samples and Passages 00
CLDN expression alterations from original tissue samples to p.00 were analysed in cultures
DT14/06R, DT14/06T, DT14/06TS, DT14/07T, DT14/08R and DT14/09T, as RNA from tissue samples
and lysates from the first cultivated cells were available.
CLDN Expression in the Latest Analysed Passage
CLDN expression was declared as “high”, if the expression level in the latest analysed passage was
higher than cut off 0.1, as “low”, if the expression level was lower than cut off 0.1. Normalization was
performed towards the reference genes ACTB and GAPDH, all values refer to the reference gene value 1.
Linear Correlation of CLDN Expression during Cultivation
The correlation coefficient according to Pearson is an empirical correlation coefficient and can
be applied to calculate linear correlations between two time-dependent gene expression profiles,
which were obtained from the cultivation of cell lines T120A, T124 and DT14/04T. The correlation
coefficient is defined by the following equation:
Kore(x, y) =
∑ni=1 (xi − xm)× (yi − ym)√
∑ni=1 (xi − xm)2 ×∑ni=1 (yi − ym)2
in which x and y are passage series for two different CLDNs of the same cell line. “xm” and “ym” are
the mean values of the CLDN gene expression data of a passage series in a certain cell line. For a better
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visibility of correlations, each value of each CLDN gene expression profile was scaled with a factor.
The value of the factor is equal to the mean value of the expression time series such that all scaled
expression profiles have the same mean value.
4.2.2. CLDN Gene Expression Analyses Using Conventional PCR
cDNA-Synthesis
cDNA was synthesised using M-MLV-Reverse Transcriptase (Promega), 500 ng of total RNA
and AP2-Primer according to the manufacturer´s instructions. Two negative process controls were
included. To check reagents for contamination, a negative control was performed once for each run that
included the reverse transcriptase but no RNA, so that no cDNA was synthesisable from sample RNA.
To check the RNA for contamination, an additional negative control was performed for each sample
and included RNA but no reverse transcriptase, so that cDNA could not be synthesised from the
RNA. Genomic DNA contamination was excluded in cDNA and negative controls using a PCR assay
(CXCR4 upVIIIa/CXCR4 lo VIII) for an intron sequence of the reference gene C-X-C chemokine receptor
type 4 (cxcr4) which can only be found on genomic DNA, but not on cDNA. Integrity of the RNA and
thereby cDNA quality of all samples was tested using a PCR assay for the reference gene ACTB (ACTB
up/ACTB lo). cDNA was further analysed if contaminations were excluded in the cDNA and negative
controls and if integrity of RNA was verified. Primer sequences have been published previously [27].
CLDN Gene Expression Analyses: Conventional PCR
CLDN-1, -3, -4 and -7 gene expressions were analysed in 1 µL cDNA of an early and late
passage of cell cultures T120A, T121, T124, DT14/04R, DT14/04T, DT14/06T and DT14/10, using PCR
assays (CLDN-1: CL_1_up1/CL_1_lo1; CLDN-3: CL_3_up1/CL_3_lo1; CLDN-4: CL_4_up1/CL_4_lo1;
CLDN-7: CL_7_up1/CL_7_lo1) and real-time PCR primer assays (CLDN-1: CL1 sg up1/CL1 sg lo1;
CLDN-3: CL3 sg up3/CL3 sg lo3; CLDN-4: CL4 sg up1/CL4 sg lo1; CLDN-7: CL7 sg up1/CL7 sg lo2)
for conventional PCR, as published previously [27]. The standard protocol for conventional PCR
contained initial denaturation at 95 ◦C for 10 min; followed by 35 cycles: denaturation at 95 ◦C for 30 s,
annealing at 60 ◦C for 30 s and elongation at 72 ◦C for 1 min for PCR assays or 30 s for real-time PCR
assays; followed by the final elongation at 72 ◦C for 5 min.
4.3. Immunocytochemistry
For immunocytochemical characterisation of the cytokeratin distribution in the cell cultures, cell
pellets from early and late passages of the cultured cells were detached with TrypLETM Express Enzyme
(Thermo Fischer Scientific, Darmstadt, Germany) followed by mechanical scraping (Cell Scraper M,
TPP, Trasadingen, Switzerland) if enzymatic detachment was incomplete. Detached cells were
centrifuged at 1000× g for 10 min, fixed in 4% paraformaldehyde and embedded in paraffin wax.
Pellets of all primary cultures and cell lines were immunocytochemically stained with a panel
of antibodies detecting various cytokeratins (CK), for details see Tables 2 and 3. In addition,
pellets of the primary culture DT14/04R and cell lines T120A, T121, T124, DT14/04T, DT14/06T
and DT14/10 were further investigated using antibodies specific for the CLDN-1, -3, -4 and
-7 proteins according to Table 5. Immunocytochemistry was performed on serial sections according to
standard procedures as described previously [43]. Briefly, antigen retrieval was achieved by
incubation in a citrate buffer (pH 6.0, 20 min, 95 ◦C) followed by inhibition of endogenous
peroxidase activity with 0.5% H2O2 in 70% ethanol for 30 min, and blocking of non-specific
binding with inactivated goat serum (diluted 1:5 in phosphate-buffered saline, PBS, pH 7.2).
Primary antibodies were applied for 1 h at ambient temperature (for anti-CLDN antibodies) or
overnight at 4 ◦C (for anti-CK antibodies) followed by incubation with biotinylated goat anti-mouse
or goat anti-rabbit secondary antibodies (Vector Laboratories, Burlingame, CA, USA), respectively.
Subsequently, avidin-biotin-peroxidase reagent (Vector Laboratories) was used according to the
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manufacturer’s instructions for 30 min and for anti-CLDN antibodies amplification was achieved using
biotinylated tyramine as described elsewhere [44]. Supplemented with H2O2, 3,3′-diaminobenzidine
(Sigma Aldrich, Munich, Germany) was applied to induce a brown colour reaction, and sections were
counterstained with Mayer’s haematoxylin.
Table 5. List of antibodies used for immunocytochemistry (ICC) and immunofluorescence (IF). Staining
pattern of all antibodies is identical to that described in the literature. “*” cross-reactivity with canine
according to manufacturer’s information, “**” the canine KRT14 gene is a homolog of the human KRT14
gene (National Center for Biotechnology Information HomoloGene). Cross reactivity of the antibody is
highly presumable as amino acid sequences of the human (NP_00517.2) and canine (NP_001240670.1)
cytokeratin 14 reveal an identity of 97% (according to National Center for Biotechnology Protein Blast).
Protein Antibody
Dilution
ICC IF
CLDN-1 Polyclonal rabbit anti-human CLDN-1 antibody(Thermo Fischer Scientific, Darmstadt, Germany) * 1:50 1:50
CLDN-3 Polyclonal rabbit anti-mouse CLDN-3 antibody(Thermo Fischer Scientific) * 1:200 1:83
CLDN-4 Monoclonal mouse anti-human CLDN-4 antibody(Clone 3E2C1, Thermo Fischer Scientific) * 1:200 1:83
CLDN-7 Polyclonal rabbit anti-human CLDN-7 antibody(Thermo Fischer Scientific) * 1:200 1:125
Pan-CK (CK1-8, CK10,
CK13-16, CK19)
Monoclonal mouse anti-human CK
(clone AE1/AE3, Dako, Hamburg, Germany) [45–47] 1:500 -
Pan-CK (CK5, CK6, CK8,
CK17, CK19) Monoclonal mouse anti-human CK (clone MNF116, Dako) [46] * 1:1000 -
Pan-CK (CK1, CK5,
CK10, CK14)
Monoclonal mouse anti-human CK, high molecular weight
(clone 34bE12, Dako) [48] 1:500 -
CK5 and CK6 Monoclonal mouse anti-human CK5/CK6 (clone D5/16B4, Dako) [49] 1:100 -
CK7 Monoclonal mouse anti-human CK7 (clone OV-TL12/30, Dako) [47] 1:100 -
CK10 Monoclonal mouse anti-human CK10 (clone DE-K10, Dako) [50] * 1:100 -
CK14 Polyclonal rabbit anti-human CK14 (Thermo Fischer Scientific) ** 1:500 -
CK20 Monoclonal mouse anti-human CK20 (clone Ks20.8, Dako) [47] * 1:100 -
4.4. Immunofluorescence
Immunofluorescence was performed for cell cultures T120A, p.37–42; T124, p.15; DT14/04T,
p.4 and p.16–19; and DT14/06T, p.44–49. The cells were cultivated on collagen coated cover slips.
After achieving a confluency of about 75%, the cells were fixed with 4% formaldehyde for 10 min at
room temperature and permeabilized with 0.3% Triton X-100 in PBS for 15 min at 37 ◦C. BSA (bovine
serum albumin, 1%) in PBS was used for 30 min at 37 ◦C to block and saturate the non-specific
binding positions. Then the cells were stained over night at 4 ◦C for CLDN-1, -3, -4 and -7 proteins
with the respective primary antibodies according to Table 5. The secondary fluorescein conjugated
anti-rabbit (Merck Millipore, Darmstadt, Germany) and fluorescein isothiocyanate (FITC) conjugated
anti-mouse (Merck Millipore) were diluted 1:100 in PBS containing 1% BSA and added to the cells
with 2 µM DAPI (Sigma-Aldrich, Munich, Germany) for 1 h at 37 ◦C. The cells were stored in PBS
at 4 ◦C for further analysis. As a control for unspecific binding sites, cells were also incubated only
with the secondary antibodies. The fluorescent images of the cells were collected with a Nikon
Eclipse TE2000-E confocal laser scanning microscope (400 nm for Dapi and 488 nm for the CLDN
proteins), with a 60× water immersion objective and EZ-C1 3.80 software program (Nikon, Düsseldorf,
Germany). Image processing was performed using the ImageJ plugin named FigureJ [51].
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